The review analyses 47 publications that follow the pathway of clofazimine from its discovery to recognition as a Group B drug for treatment of multiple drug resistant tuberculosis. It describes its mechanism of action and effects on Mycobacterium tuberculosis, pharmacokinetics, and safety parameters
ABSTRAm This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, cl...
Limited data are available regarding the in vitro activity of clofazimine against nontuberculous myc...
The 2016 World Health Organization treatment recommendations for drug-resistant tuberculosis (DR-TB)...
Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (D...
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-infl...
AbstractClofazimine has shown activity against Mycobacterium tuberculosis, including multidrug-resis...
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-infl...
Background. Treatment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tubercul...
The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however,...
The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course re...
The increased incidence of drug-resistant tuberculosis has created an urgent necessity for the devel...
Objectives: Given the spread of multidrug-resistant tuberculosis (MDR-TB), new therapies are urgentl...
The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberc...
Background Current anti-tuberculosis therapeutics are not sufficiently effective against drug-resist...
Although chemotherapeutic treatment regimens are currently available, and considerable effort has be...
ABSTRAm This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, cl...
Limited data are available regarding the in vitro activity of clofazimine against nontuberculous myc...
The 2016 World Health Organization treatment recommendations for drug-resistant tuberculosis (DR-TB)...
Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (D...
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-infl...
AbstractClofazimine has shown activity against Mycobacterium tuberculosis, including multidrug-resis...
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-infl...
Background. Treatment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tubercul...
The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however,...
The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course re...
The increased incidence of drug-resistant tuberculosis has created an urgent necessity for the devel...
Objectives: Given the spread of multidrug-resistant tuberculosis (MDR-TB), new therapies are urgentl...
The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberc...
Background Current anti-tuberculosis therapeutics are not sufficiently effective against drug-resist...
Although chemotherapeutic treatment regimens are currently available, and considerable effort has be...
ABSTRAm This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, cl...
Limited data are available regarding the in vitro activity of clofazimine against nontuberculous myc...
The 2016 World Health Organization treatment recommendations for drug-resistant tuberculosis (DR-TB)...
DOI
Add to ORKG